CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Viatris Inc. - VTRS CFD

10.93
0.46%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.31
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 10.98
Open* 10.91
1-Year Change* -1.62%
Day's Range* 10.9 - 10.9
52 wk Range 8.42-15.6
Average Volume (10 days) 10.0109
Average Volume (3 months) 216.102
Market Cap 13424.4
P/E Ratio 16.7799
Shares Outstanding 1212680000
Revenue 16728.3
EPS 0.65972
Dividend (Yield %) 4.33604
Beta 1.20212
Next Earnings Date Feb 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 25, 2022 10.93 -0.01 -0.09% 10.94 11.11 10.87
Nov 23, 2022 10.98 0.05 0.46% 10.93 11.04 10.85
Nov 22, 2022 11.03 0.10 0.91% 10.93 11.06 10.92
Nov 21, 2022 11.06 0.07 0.64% 10.99 11.09 10.82
Nov 18, 2022 10.98 0.04 0.37% 10.94 11.01 10.83
Nov 17, 2022 10.93 0.06 0.55% 10.87 10.98 10.81
Nov 16, 2022 11.04 -0.21 -1.87% 11.25 11.31 10.95
Nov 15, 2022 11.29 -0.34 -2.92% 11.63 11.80 11.24
Nov 14, 2022 11.55 0.29 2.58% 11.26 11.66 11.26
Nov 11, 2022 11.40 0.09 0.80% 11.31 11.49 11.16
Nov 10, 2022 11.30 0.19 1.71% 11.11 11.39 11.02
Nov 9, 2022 10.80 -0.18 -1.64% 10.98 11.01 10.79
Nov 8, 2022 11.08 0.18 1.65% 10.90 11.26 10.72
Nov 7, 2022 10.94 0.66 6.42% 10.28 11.40 10.24
Nov 4, 2022 9.68 -0.03 -0.31% 9.71 9.84 9.49
Nov 3, 2022 9.62 -0.27 -2.73% 9.89 9.89 9.62
Nov 2, 2022 10.03 -0.14 -1.38% 10.17 10.28 10.02
Nov 1, 2022 10.22 0.10 0.99% 10.12 10.27 10.03
Oct 31, 2022 10.10 0.12 1.20% 9.98 10.12 9.95
Oct 28, 2022 10.03 0.12 1.21% 9.91 10.15 9.87

Viatris Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 11076.9 11907.7 11433.9 11500.5 11946 17886.3
Revenue 11076.9 11907.7 11433.9 11500.5 11946 17886.3
Cost of Revenue, Total 6185.4 6931.5 6861.9 6948.6 7404.2 11326.4
Gross Profit 4891.5 4976.2 4572 4551.9 4541.8 6559.9
Total Operating Expense 10533.3 10484.4 10553.7 10795.7 12173.6 17928.3
Selling/General/Admin. Expenses, Total 2241.4 2360.3 2274.3 2416.9 2571.4 3893.6
Research & Development 697.8 657.2 568.7 518.8 507.5 654.6
Unusual Expense (Income) 1408.7 535.4 848.8 911.4 1690.5 2053.7
Operating Income 543.6 1423.3 880.2 704.8 -227.6 -42
Interest Income (Expense), Net Non-Operating -495.5 -493.9 -566.2 -587.3 -548.4 -700.2
Other, Net 73.6 -26.4 -15.6 36.9 54.8 77.8
Net Income Before Taxes 121.7 903 298.4 154.4 -721.2 -664.4
Net Income After Taxes 480 824.6 338 16.8 -669.9 -1269.1
Minority Interest 0 0
Net Income Before Extra. Items 480 824.6 338 16.8 -669.9 -1269.1
Net Income 480 696 352.5 16.8 -669.9 -1269.1
Income Available to Common Excl. Extra. Items 480 824.6 338 16.8 -669.9 -1269.1
Income Available to Common Incl. Extra. Items 480 696 352.5 16.8 -669.9 -1269.1
Diluted Net Income 480 696 352.5 16.8 -669.9 -1269.1
Diluted Weighted Average Shares 520.5 536.7 516.5 516.5 601.2 1208.8
Diluted EPS Excluding Extraordinary Items 0.92219 1.53643 0.6544 0.03253 -1.11427 -1.04988
Diluted Normalized EPS 2.68137 2.44739 1.72259 1.1795 0.71345 0.05444
Total Extraordinary Items -128.6 14.5
Dividends per Share - Common Stock Primary Issue 0.33
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 4430.3 4577.8 4536.6 4341.6 4191.7
Revenue 4430.3 4577.8 4536.6 4341.6 4191.7
Cost of Revenue, Total 2962.6 3071 2734 2558.8 2357.4
Gross Profit 1467.7 1506.8 1802.6 1782.8 1834.3
Total Operating Expense 4696.5 4625.6 4181.3 4424.9 3485.8
Selling/General/Admin. Expenses, Total 966.2 980.4 980.5 966.5 819.5
Research & Development 163 143.8 153.1 194.7 142
Unusual Expense (Income) 604.7 430.4 313.7 704.9 166.9
Operating Income -266.2 -47.8 355.3 -83.3 705.9
Interest Income (Expense), Net Non-Operating -186.7 -175 -165.7 -155.2 -146.3
Other, Net 11.6 3.7 10.3 34.6 -32.1
Net Income Before Taxes -441.3 -219.1 199.9 -203.9 527.5
Net Income After Taxes -1037.6 -279.2 311.5 -263.8 399.2
Net Income Before Extra. Items -1037.6 -279.2 311.5 -263.8 399.2
Net Income -1037.6 -279.2 311.5 -263.8 399.2
Income Available to Common Excl. Extra. Items -1037.6 -279.2 311.5 -263.8 399.2
Income Available to Common Incl. Extra. Items -1037.6 -279.2 311.5 -263.8 399.2
Diluted Net Income -1037.6 -279.2 311.5 -263.8 399.2
Diluted Weighted Average Shares 1207.5 1208.8 1212.6 1209.4 1213.1
Diluted EPS Excluding Extraordinary Items -0.8593 -0.23097 0.25689 -0.21812 0.32907
Dividends per Share - Common Stock Primary Issue 0 0.11 0.11 0.11 0.12
Diluted Normalized EPS -0.53378 0.00046 0.42504 0.16073 0.43319
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 7522.5 7213.3 6367.7 6757.3 12867.5 10902.9
Cash and Short Term Investments 1112.1 402.7 445.6 541.4 929.3 790.4
Cash & Equivalents 998.8 292.1 388.1 475.6 844.4 701.2
Short Term Investments 113.3 110.6 57.5 65.8 84.9 89.2
Total Receivables, Net 3310.9 3612.4 2881 3058.8 4843.8 4266.4
Accounts Receivable - Trade, Net 3310.9 3173.1 2416.5 2640.1 3891.3 3774.4
Total Inventory 2456.4 2542.7 2580.2 2670.9 5471.9 3977.7
Prepaid Expenses 169.1 119.8 130.6 156.7 267.8 256.7
Other Current Assets, Total 474 535.7 330.3 329.5 1354.7 1611.7
Total Assets 34726.2 35806.3 32734.9 31255.5 61553 54842.8
Property/Plant/Equipment, Total - Net 2322.2 2339.1 2170.2 2404.2 3783.5 3479.4
Property/Plant/Equipment, Total - Gross 3807.9 4002.2 3974.5 4377.5 6045.5 5879.9
Accumulated Depreciation, Total -1485.7 -1663.1 -1804.3 -1973.3 -2262 -2400.5
Goodwill, Net 9231.9 10205.7 9747.8 9590.6 12347 12113.7
Intangibles, Net 14447.8 15245.8 13664.6 11649.9 29683.2 26134.2
Long Term Investments 396.4 226 138.7 92.2 47.9 0
Other Long Term Assets, Total 805.4 576.4 645.9 761.3 2823.9 2212.6
Total Current Liabilities 5040.7 6385.3 4587.8 5569.1 10562.9 9884.4
Accounts Payable 1348.1 1452.5 1617 1528.1 1345.7 1056.1
Accrued Expenses 1980.2 1506 1279.2 1563.6 2735.9 3226.4
Notes Payable/Short Term Debt 46.4 46.5 1.9 0 1100.9 1493
Current Port. of LT Debt/Capital Leases 290 1808.9 655.2 1457.6 2256.3 1860.3
Other Current Liabilities, Total 1376 1571.4 1034.5 1019.8 3124.1 2248.6
Total Liabilities 23610 22498.7 20567.8 19371.7 38598.9 34350.1
Total Long Term Debt 15202.9 12865.3 13161.2 11214.3 22429.2 19717.1
Long Term Debt 15202.9 12865.3 13161.2 11214.3 22429.2 19717.1
Deferred Income Tax 2006.4 2012.4 1722 1627.5 3123.7 2815
Minority Interest 1.4 0
Other Liabilities, Total 1358.6 1235.7 1096.8 960.8 2483.1 1933.6
Total Equity 11116.2 13307.6 12167.1 11883.8 22954.1 20492.7
Common Stock 6 6 6 6.1 12.1 12.1
Additional Paid-In Capital 8499.3 8586 8591.4 8643.5 18438.8 18536.1
Retained Earnings (Accumulated Deficit) 4942.1 5644.5 6010.7 6031.1 5361.2 3688.8
Treasury Stock - Common -67.5 -567.7 -999.7 -999.7 0
Unrealized Gain (Loss) 14.5 10.1 0 0.6 1.2 0
Other Equity, Total -2278.2 -371.3 -1441.3 -1797.8 -859.2 -1744.3
Total Liabilities & Shareholders’ Equity 34726.2 35806.3 32734.9 31255.5 61553 54842.8
Total Common Shares Outstanding 535.328 524.207 515.799 516.149 1206.9 1209.51
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 12318.5 11749.8 11308.4 10902.9 11744.3
Cash and Short Term Investments 892.3 762 844.3 790.4 837
Cash & Equivalents 806.9 673.9 756.6 701.2 752.4
Short Term Investments 85.4 88.1 87.7 89.2 84.6
Total Receivables, Net 4529 4478.7 4345.5 4266.4 4093.9
Accounts Receivable - Trade, Net 3889.6 3880.4 3841.5 3774.4 3556.9
Total Inventory 4942.2 4487.6 4081.9 3977.7 3797.3
Prepaid Expenses 259.9 221.6 237.3 256.7 268.1
Other Current Assets, Total 1695.1 1799.9 1799.4 1611.7 2748
Total Assets 58979.2 57984.1 56070.4 54842.8 53466.9
Property/Plant/Equipment, Total - Net 3558.3 3472 3419.9 3479.4 3431.9
Property/Plant/Equipment, Total - Gross 5927.1 5963.7 5903.7 5879.9 5374.2
Accumulated Depreciation, Total -2368.8 -2491.7 -2483.8 -2400.5 -1942.3
Goodwill, Net 11907.3 11990.4 12169.5 12113.7 10978.8
Intangibles, Net 28489.6 27863.7 26987 26134.2 25251.8
Long Term Investments 33.6 24.2 11.6 0
Other Long Term Assets, Total 2671.9 2884 2174 2212.6 2060.1
Total Current Liabilities 9978.1 10132.6 10103.9 9884.4 9642.9
Accounts Payable 1549.7 1319.5 1139 1056.1 928.4
Accrued Expenses 2918.4 2778.4 3145.4 3226.4 2848.3
Notes Payable/Short Term Debt 36.9 1300.5 1706.9 1493 655.4
Current Port. of LT Debt/Capital Leases 2255.3 2148.4 1881 1860.3 2595.4
Other Current Liabilities, Total 3217.8 2585.8 2231.6 2248.6 2615.4
Total Liabilities 37564.5 36777.2 34929.1 34350.1 33019.2
Total Long Term Debt 22102.2 20917 19854.3 19717.1 18762.5
Long Term Debt 22102.2 20917 19854.3 19717.1 18762.5
Deferred Income Tax 3014.6 3485.7 2918 2815 2729.5
Other Liabilities, Total 2469.6 2241.9 2052.9 1933.6 1884.3
Total Equity 21414.7 21206.9 21141.3 20492.7 20447.7
Common Stock 12.1 12.1 12.1 12.1 12.1
Additional Paid-In Capital 18464.6 18489.9 18514.1 18536.1 18555.1
Retained Earnings (Accumulated Deficit) 4323.6 3909.9 4087 3688.8 3941.5
Unrealized Gain (Loss) 0.2 0.4 0.3 0 -1.3
Other Equity, Total -1385.8 -1205.4 -1472.2 -1744.3 -2059.7
Total Liabilities & Shareholders’ Equity 58979.2 57984.1 56070.4 54842.8 53466.9
Total Common Shares Outstanding 1208.53 1209.21 1209.38 1209.51 1212.32
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 480 696 352.5 16.8 -669.9 -1269.1
Cash From Operating Activities 2047.2 2064.8 2341.7 1803.7 1231.8 3016.9
Cash From Operating Activities 1523 1805.8 2109.9 2019.3 2216.1 4506.5
Deferred Taxes -609.5 -111.4 -264.3 -192.6 -213.2 675.7
Non-Cash Items 1463.2 356.8 332.6 468 595.1 908.6
Cash Taxes Paid 285.6 285.7 228.6 278.6 324.4 641.7
Cash Interest Paid 357.2 474 460.8 470.6 555.4 684.8
Changes in Working Capital -809.5 -682.4 -189 -507.8 -696.3 -1804.8
Cash From Investing Activities -7677.8 -976.4 -1210.4 -525.4 -301.1 -117.8
Capital Expenditures -750.6 -896.2 -1195.6 -406 -681.2 -509.4
Other Investing Cash Flow Items, Total -6927.2 -80.2 -14.8 -119.4 380.1 391.6
Cash From Financing Activities 5344.6 -1893.1 -1090.9 -1169 -605.7 -3012
Financing Cash Flow Items -165.9 -51.2 -45 -74.2 -205 -513.9
Issuance (Retirement) of Stock, Net 13.8 -482.4 -414.2 8.1 0.6 0
Issuance (Retirement) of Debt, Net 5496.7 -1359.5 -631.7 -1102.9 -401.3 -2099.1
Foreign Exchange Effects -9.6 27.6 -21 -7.5 33.8 -30.9
Net Change in Cash -295.6 -777.1 19.4 101.8 358.8 -143.8
Total Cash Dividends Paid -399
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -1037.6 -1316.8 -1005.3 -1269.1 399.2
Cash From Operating Activities 848.8 1408.2 2493.8 3016.9 1138.5
Cash From Operating Activities 1422.5 2739.6 3756.7 4506.5 736
Deferred Taxes 288.4 581.6 728.6 675.7 -52.8
Non-Cash Items 106.8 344.2 479.1 908.6 71.2
Changes in Working Capital 68.7 -940.4 -1465.3 -1804.8 -15.1
Cash From Investing Activities 236.3 219.5 101.3 -117.8 -66.9
Capital Expenditures -53.2 -156.1 -288 -509.4 -71.9
Other Investing Cash Flow Items, Total 289.5 375.6 389.3 391.6 5
Cash From Financing Activities -1099.8 -1785.3 -2662.8 -3012 -1009
Financing Cash Flow Items -35.9 -501.4 -512.3 -513.9 -26
Issuance (Retirement) of Stock, Net 0 0 0
Issuance (Retirement) of Debt, Net -1063.9 -1150.9 -1884.5 -2099.1 -837.9
Foreign Exchange Effects -22.2 -13.3 -20.6 -30.9 -11.4
Net Change in Cash -36.9 -170.9 -88.3 -143.8 51.2
Total Cash Dividends Paid -133 -266 -399 -145.1

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Viatris Inc. Company profile

Viatris (VTRS) is a global healthcare company. It was formed in 2020 through the merger of Pfizer’s (PFE) off-patent branded and generic medicines division Upjohn and pharmaceutical firm Mylan. 

The merger of Mylan and Upjohn was announced in July 2019 and received final regulatory clearance in October 2020. Pfizer shareholders own 57% of Viatris and Mylan shareholders own 43%, according to the merger announcement. Viatris started trading on the Nasdaq Stock Exchange under the ticker VTRS in November 2020. 

Viatris is headquartered in Canonsburg, Pittsburgh, US. The company is operational in over 165 countries and has global centres in Shanghai, China and Hyderabad, India. 

Viatris operates about 40 manufacturing sites which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. The firm also produces numerous complex generics, biosimilars and global key brands.

Viatris offers treatment options across more than 10 major therapeutic areas covering a wide variety of non-communicable and infectious diseases. According to the company’s website, 50% of its total active pharmaceutical ingredient (API) capacity is devoted to antiretroviral (ARV), which is used against HIV infection. 

Some of the well-known and key brands under Viatris are anxiety treatment drug Xanax, antidepressant Zoloft, anti-inflammatory drug Celebrex and erectile dysfunction therapy Viagra, among others. Viatris also offers global biosimilars franchises focused on the areas of oncology, immunology, endocrinology, ophthalmology and dermatology.

Industry: Pharmaceuticals (NEC)

1000 Mylan Blvd.
CANONSBURG
PENNSYLVANIA 15317
US

Income Statement

People also watch

XRP/USD

0.40 Price
+0.340% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00262

Oil - Crude

76.62 Price
-1.870% 1D Chg, %
Long position overnight fee -0.0082%
Short position overnight fee -0.0061%
Overnight fee time 22:00 (UTC)
Spread 0.09

BTC/USD

16,583.30 Price
+0.140% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 66.00

Natural Gas

7.20 Price
-5.490% 1D Chg, %
Long position overnight fee -0.1727%
Short position overnight fee 0.1266%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading